AEGiS-UPI: Glaxo HIV drug gets label update United Press InternationalImportant note: Information in this article was accurate in 2005. The state of the art may have changed since the publication date.
Click here to return to United Press International main menu
DonateNow
Print this article




Glaxo HIV drug gets label update

United Press International - November 18, 2005


WASHINGTON - GlaxoSmithKline said Friday it has received approval for updated labeling for its HIV protease inhibitor Lexiva.

Glaxo and its partner Vertex Pharmaceuticals said the Food and Drug Administration has approved GSK's application to add to Lexiva's prescribing data that simultaneous administration of the HIV treatment in combination with esomeprazole, sold as Nexium, does not result in lowering of blood levels of Lexiva.

The company said the new information is based on a study showing that blood levels of Lexiva remained unchanged when patients took the Glaxo drug concurrently with 20 milligram once-daily esomeprazole.

Drug interactions that result in lower PI blood levels may increase the risk for virologic failure in patients treated with HIV protease inhibitors, GSK said.


051118
UP051118


Copyright © 2005 - United Press International. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through United Press International, Permissions Desk, 1510 H St. N.W. Washington DC 2005. Main Phone Switchboard: 202-898-8000 FAX: 202-898-8057 or 202-898-8147 Email: info@upi.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .